The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REJOICE-Ovarian01: Phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician’s choice in patients with platinum-resistant ovarian cancer.
 
Debra Richardson
Honoraria - Zentalis
Consulting or Advisory Role - Abbvie; Araris; AstraZeneca; Corcept Therapeutics; Daiichi Sankyo/UCB Japan; Eisai; Genmab; Gilead Sciences; GlaxoSmithKline; Immunogen; Incyclix Bio; ProfoundBio; Repare Therapeutics; Tubulis GmbH; Xencor
Research Funding - A2A Pharmaceuticals (Inst); aadi (Inst); Acrivon Therapeutics (Inst); Allorian (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); CanariaBio (Inst); Celsion (Inst); Clovis Oncology (Inst); DualityBio (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immunogen/Abbvie (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nimbus Therapeutics (Inst); Nurix (Inst); OnCusp Therapeutics (Inst); Plexxikon (Inst); PMV Pharma (Inst); ProfoundBio (Inst); Scorpion Therapeutics (Inst); Shattuck Labs (Inst); Tubulis GmbH (Inst); Valerion Therapeutics, LLC (Inst)
Travel, Accommodations, Expenses - Genmab; Society of Gynecologic Oncology
 
Kathleen Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Astellas Medivation; BIOPHARM; CEA/CCO; CME Outfitters; Congress Chanel; Curio Science; Great Debates and Updates; IDEOlogy Health; MDoutlook; Med Learning Group; Medscape; OncLive/MJH Life Sciences; Peerview; PeerVoice; Physicans' Education Resource; Plexus; Research to Practice; The Clearity Foundation; University of Arkansas for Medical Sciences; University of Florida; virtual incision
Consulting or Advisory Role - AADi; Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; BioNTech SE; Bristol Myers Squibb Foundation; Caris Life Sciences; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo Europe GmbH; Day One Biopharmaceuticals; Debiopharm Group; Duality Biologics (Inst); Eisai; Foundation Medicine; Genentech/Roche; Genmab/Seagen; GlaxoSmithKline/Tesaro (Inst); immunocore; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Karyopharm Therapeutics; Kivu; Loxo/Lilly; Merck; Mersana (Inst); natera; Novocure; OnCusp Therapeutics; ProfoundBio; Regeneron; Roche; Schrodinger (Inst); seagen; T knife; Takeda Science Foundation; Tango Therapeutics; Third Arc; Tubulis GmbH; Verastem/Pharmacyclics; Whitehawk; zentalis; zymeworks
Research Funding - Allarity Therapeutics (Inst); AstraZeneca (Inst); Daiichi Sankyo/Lilly (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Immunogen (Inst); Merck (Inst); Regeneron (Inst); Schrodinger (Inst); Torl Biotherapeutics (Inst); Verastem (Inst); Zymeworks (Inst)
Other Relationship - GOG Partners (Inst)
(OPTIONAL) Uncompensated Relationships - International Gynecologic Cancer Society
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genmab; Kyowa Kirin; MSD K.K; Regeneron; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genmab; GlaxoSmithKline; Kaken Pharmaceutical; Merck KGaA; MSD K.K; Regeneron; Roche; Takeda; Zymeworks
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Petar Jelinic
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Connor Mailley
Employment - Daiichi Sankyo
 
Sandra Re
Employment - Bristol-Myers Squibb; Daiichi Sankyo Inc
Stock and Other Ownership Interests - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan
 
Wanying Ma
Employment - Daiichi Sankyo; Novartis
Stock and Other Ownership Interests - Novartis
 
Tsvetomir Mitov
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Isabelle Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; IMMUNOCORE; Immunogen; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; PMV Pharma; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Lilly; Macrogenics; Mersana; MSD Oncology; Netris Pharma; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Scorpion Therapeutics; seagen; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES